
Bruno Daniele, MD, director, Department of Oncology and Medical Oncology, G. Rummo Hospital, Italy, discusses the potential impact of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).

Your AI-Trained Oncology Knowledge Connection!


Published: July 8th 2016 | Updated: